Lyme Disease Diagnostics Market - Global Industry Insights, Trends, 2026

Lyme disease occurs due to bacterium Borrelia burgdorferi (Bb) and is transmitted to humans through the bite of infected blacklegged ticks. Its general symptoms include fatigue, headache, fever and a skin rash called erythema migrans. The infection can spread to heart, nervous system and joints if left untreated. Centers for Disease Control and Prevention (CDC) recommends a two-step process to diagnose Lyme infection. The first step uses a testing procedure called enzyme immunoassay (EIA) or, an indirect immunofluorescence assay (IFA). If the first screening step is negative, no additional testing is required. However, if the first screening step is positive or not clear, the second screening step i.e. Western blot test is performed. Results of the screening tests are considered positive only if both the tests are positive. CDC does not recommend avoiding the first screening step as it will increase the rate of false positive results that can lead to misdiagnosis and inappropriate treatment. The ELISA and Western blot are the commonly used tests to diagnose the disease. Western blot is the most accurate antibody test, whereas ELISA tests are not sensitive enough for screening. Manufacturers could focus on developing new tests for the diagnosis of Lyme disease. However, these tests should have FDA approval and exhibit high performance.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1608

Lyme Disease Diagnostics Market Dynamics

Lyme disease is a difficult medical condition to identify as it can be confused with increasing cases of tick-borne infectious diseases, emergence of new vector-borne diseases, and the complexity and variations of symptoms in each patient. Rising prevalence of Lyme disease and increasing focus of governments towards improvement of healthcare facilities is expected to drive growth of the Lyme disease diagnostics market during the forecast period. According to the National Institute of Allergy and Infectious Diseases (NIAID) 2016 report, there are over 300,000 reported cases of Lyme disease, annually in the U.S. alone. Various government organizations and institutes such as NIAID are working towards improving Lyme disease diagnostics. NIAID actively supports research on Lyme disease diagnostics. In collaboration with CDC, NIAID plays a key role in encouraging development of new methods to improve Lyme disease screening in people with co-infections such as the tick-borne infections. The institute is actively supporting research on Lyme disease diagnostics. NIAID grantees directly work in collaboration with CDC researchers to compare and evaluate the effectiveness of existing diagnostic methods.

Moreover, industry players are focusing on research and development of new tests for Lyme disease diagnosis and this is expected to aid in growth of the Lyme disease diagnostics market. For instance, in 2017, IGeneX Inc.—a Clinical Laboratory Improvement Amendments (CLIA) and New York-approved Reference Laboratory, specializing in testing for tick-borne diseases— launched three new tests that are more comprehensive and specific for assisting in diagnosis of tick-borne relapsing fever and Lyme disease. However, lack of awareness about the disease and inefficiency in Lyme disease testing significantly affects the market growth.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/lyme-disease-diagnostics-market-1608

Several individuals with Lyme-like symptoms are wrongly diagnosed, owing to existing serological tests that cannot identify antibodies of all the different strains of B. burgdorferi. Therefore, demand for better diagnostic tests for the disease is increasing. Since the symptoms of tick-borne relapsing fever and Lyme are similar, development of more accurate test is required for proper diagnosis.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://globalresearchtrends.blogspot.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.